Announcements Trials

Browse Landscape

Status

Recruiting 4 Active not recruiting 3 Completed 2 Withdrawn 1 Terminated 1 Available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Interventions

3-Iodobenzylguanidine 4 tempol 2 balstilimab 2 zolbetuximab 1 zipalertinib 1 venetoclax 1 ulixertinib 1 tisagenlecleucel 1 tipifarnib 1 tebentafusp 1 talazoparib 1 sodium thiosulfate 1 selinexor 1 ruxolitinib 1 ribociclib 1 osunprotafib 1 nirogacestat 1 mirdametinib 1 mifamurtide 1 lifileucel 1 leronlimab 1 idecabtagene vicleucel 1 gedatolisib 1 fluorodopa F 18 1 fluorocholine 1 epigallocatechin gallate 1 ensartinib 1 dodecyl maltoside 1 carbon-11 methionine 1 burosumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Available × lifileucel × Clear all

NCT05398640 2026-04-20

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

Iovance Biotherapeutics, Inc.

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡